Mineralys Therapeutics Reports Q3 2024 Results and Clinical Progress
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has released its financial results for the third quarter ending September 30, 2024, alongside key updates on its clinical trials. The company
Mineralys Therapeutics Announces Q3 2024 Results and Updates
Mineralys Therapeutics, Inc. ( (MLYS) ) has released its Q3 earnings. Here is a breakdown of the information Mineralys Therapeutics, Inc.
Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 – – Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate delivering topline data in mid first half of 2025 – – Ongoing enrollment in Explore-CKD Phase 2 trial and anticipate delivering topline data in Q2 2025 – – Conference call today at 4:30 p.
Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights
AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, to complete enrollment in the first half of 2025Expect to announce topline results
Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update
Completed a successful end of Phase 2 meeting with the FDA for bitopertin in erythropoietic protoporphyria (EPP), reaching alignment on all
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024
Preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by year-end 2024 BOSTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers,
Buy Rating on Mineralys Therapeutics Driven by Lorundrostat’s Potential in Hypertension Treatment
Mineralys Therapeutics, Inc. (MLYS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today.
Medscape1d
Management of Hypertension in Chronic Heart Failure
Hypertension (HTN) increases the risk of development of HF and it precedes it in 75% of cases. HF patients are nearly evenly divided between those with reduced left ventricular (LV) function or ...
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2024 Earnings Call Transcript
Greetings. Welcome to Mineralys Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a ...
Endovascular Today17d
Medtronic’s Symplicity Spyral RDN Evaluated at 2 Years in SPYRAL HTN-ON MED
Medtronic announced new long-term data from the SPYRAL HTN-ON MED clinical trial of the company’s Symplicity Spyral renal ...
4 in 10 U.S. adults with hypertension don’t know they have it
Men were more likely than women to have high blood pressure, federal officials found, but men were also less likely than women to know they had hypertension.
Onlymyhealth3d
Is 16/8 Fasting Really Good for Your Health? Experts Weigh In
While 16/8 fasting may offer health benefits, it’s not suitable for everyone. "Individuals with diabetes, hypoglycaemia, or ...
Queen Mary University of London2y
SCRATCH-HTN
SCRATCH-HTN aims to explore a new way of managing high blood pressure (BP), specifically in people who have raised BP despite being on antihypertensive medications. Participants will use an external ...
Baylor College of Medicine5y
Age-based Pediatric Blood Pressure Reference Charts
The strong association of both overweight and obesity with elevated BP and hypertension (HTN) was thought to bias the previous results. (See Flynn et al, Pediatrics, 2017) Blood pressure is not ...
Q3 2024 Mineralys Therapeutics Inc Earnings Call
Greetings. Welcome to Mineralys third-quarter 2024 financial results conference call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce Dan ...